Growth of Major Depressive Disorder Market in Current and Future Players in New Research Report Available at ReportsnReports.com

ReportsnReports.com adds “PharmaPoint Major Depressive Disorder - Current and Future Players” to its store. Order a purchase copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=288099.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
ReportsnReports.com

ReportsnReports.com

Dallas, Texas (PRWEB) June 12, 2014

“PharmaPoint: Major Depressive Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Major Depressive Disorder Market. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market.

Companies Mentioned in this report are: Lundbeck, Forest Laboratories (Actavis), Eli Lilly, Pfizer, Otsuka Pharmaceutical, AstraZeneca, Takeda Pharmaceutical, Alkermes, Euthymics , ioscience, Naurex, e-Therapeutics.

Order a purchase copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=288099.

Scope

  •     Investigation of current and future market competition for Major Depressive Disorder.
  •     Competitor assessment
  •     Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  •     Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  •     Gain a high level view of the trends shaping and driving Major Depressive Disorder market.
  •     Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  •     Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  •     What’s the next big thing in the global Major Depressive Disorder market landscape? Identify, understand and capitalize

Complete Report Available at http://www.reportsnreports.com/reports/288099-pharmapoint-major-depressive-disorder-current-and-future-players.html.

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 13
3 Market Outlook 14
3.1 Global 14
3.1.1 Forecast 14
3.1.2 Drivers and Barriers - Global Issues 18
4 Current and Future Players 20
4.1 Overview 20
4.2 Trends in Corporate Strategy 23
4.3 Company Profiles 24
4.3.1 Lundbeck 24
4.3.2 Forest Laboratories (Actavis) 28
4.3.3 Eli Lilly 31
4.3.4 Pfizer 32
4.3.5 Otsuka Pharmaceutical 34
4.3.6 AstraZeneca 37
4.3.7 Takeda Pharmaceutical 38
4.3.8 Alkermes 40
4.3.9 Euthymics Bioscience 42
4.3.10 Naurex 44
4.3.11 e-Therapeutics 46
5 Appendix 49
5.1 Bibliography 49
5.2 Abbreviations 50
5.3 Methodology 52
5.4 Forecasting Methodology 52
5.4.1 Diagnosed MDD Patients 52
5.4.2 Percent of Drug-Treated Patients 52
5.4.3 General Pricing Assumptions 53
5.4.4 Generic Erosion 54
5.5 Physicians and Specialists Included in this Study 54
5.6 About the Authors 56
5.6.1 Analyst 56
5.6.2 Therapy Area Directors 56
5.6.3 Global Head of Healthcare 57
5.7 About GlobalData 58
5.8 Disclaimer 58

1.1 List of Tables
Table 1: Global Sales Forecasts ($) for MDD, 2013-2023 16
Table 2: MDD Market - Drivers and Barriers, 2013-2023 18
Table 3: Key Companies in the MDD Market in the 7MM and Australia, 2013 22
Table 4: Lundbeck’s MDD Portfolio Assessment, 2013 26
Table 5: Forest (Actavis)’s MDD Portfolio Assessment, 2013 29
Table 6: Eli Lilly’s MDD Portfolio Assessment, 2013 31
Table 7: Pfizer’s MDD Portfolio Assessment, 2013 33
Table 8: Otsuka’s MDD Portfolio Assessment, 2013 35
Table 9: AstraZeneca’s MDD Portfolio Assessment, 2013 37
Table 10: Takeda’s MDD Portfolio Assessment, 2013 39
Table 11: Alkermes’s MDD Portfolio Assessment, 2013 41
Table 12: Euthymics Bioscience’s MDD Portfolio Assessment, 2013 43
Table 13: Naurex’s MDD Portfolio Assessment, 2013 45
Table 14: e-Therapeutics’s MDD Portfolio Assessment, 2013 47
Table 15: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 55

1.2 List of Figures
Figure 1: Global Sales for MDD by Region, 2013-2023 17
Figure 2: Company Portfolio Gap Analysis in MDD, 2013-2023 23
Figure 3: Lundbeck SWOT Analysis in MDD, 2013-2023 27
Figure 4: Forest (Actavis) SWOT Analysis in MDD, 2013-2023 30
Figure 5: Eli Lilly SWOT Analysis in MDD, 2013-2023 32
Figure 6: Pfizer SWOT Analysis in MDD, 2013-2023 34
Figure 7: Otsuka SWOT Analysis in MDD, 2013-2023 36
Figure 8: AstraZeneca SWOT Analysis in MDD, 2013-2023 38
Figure 9: Takeda SWOT Analysis in MDD, 2013-2023 40
Figure 10: Alkermes SWOT Analysis in MDD, 2013-2023 42
Figure 11: Euthymics Bioscience SWOT Analysis in MDD, 2013-2023 44
Figure 12: Naurex SWOT Analysis in MDD, 2013-2023 46
Figure 13: e-Therapeutics SWOT Analysis in MDD, 2013-2023 48

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.